No Data
No Data
No Data
Elite Pharmaceuticals GAAP EPS of $0.00, Revenue of $15.54M
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 Ended December 31, 2023 and Provides Conference Call Information
Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty phar
Notable Earnings After Wednesday's Close
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "
Elite Pharmaceuticals Files ANDA With US FDA to Market Central Nervous System Stimulant
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announ
No Data
I-am-ToTh :
BuyHighSellLow88 : Are you looking for someone to buy your shares or why are you posting this here?
AGeezy : where did you find this news?
Jaguar8 : Current short shares available now is approximately 16M shares
nilos Wayne BuyHighSellLow88: yes
View more comments...